Home LiteratureArticle Details
PMID: 17236182 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast.

The Journal of pathology ·Vol. 211 ·No. 5 ·2007-04-00 ·Pages 499-506

Speirs V, Walker RA

Abstract

Oestrogen receptor (ER) is arguably the single most important biological predictive factor that exists today. In the last 10 years or so, however, our understanding of ER biology has undergone a paradigm shift following the identification of a second ER, ERbeta, with the original ER being renamed ERalpha. A number of isoforms have additionally been described, especially for ERbeta. Our knowledge of ER signalling has also increased with the recognition of accessory co-regulatory proteins, which help direct the transcriptional cascade. Here we outline these changes and discuss what biological and clinical implications these could have in the mammary gland.

MeSH Terms
Animals Breast/physiopathology Breast Neoplasms/genetics,physiopathology Drug Resistance, Neoplasm/physiology ErbB Receptors/physiology Estrogen Receptor alpha/genetics,physiology Estrogen Receptor beta/genetics,physiology Female Humans Mice Mice, Knockout Phosphorylation Receptors, Estrogen/genetics,physiology Receptors, Progesterone/physiology Signal Transduction/genetics,physiology Transcription, Genetic/genetics
Chemicals
Estrogen Receptor alpha Estrogen Receptor beta Receptors, Estrogen Receptors, Progesterone ErbB Receptors
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Speirs V
Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK.
Walker R A
Department of Cancer Studies and Molecular Medicine, Robert Kilpatrick Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK.
References (96)
96 references, click to expand
  1. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227-238.
  2. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signalling. J Biol Chem 2001; 276: 36869-36872.
  3. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930.
  4. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol 1997; 11: 353-365.
  5. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel estrogen receptor. FEBS Lett 1996; 392: 49-53.
  6. Olefsky JM. Nuclear receptor mini review series. J Biol Chem 2001; 276: 36863-36864.
  7. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993; 17: 263-265.
  8. Enmark E, Pelto-Huikko M, Grandien K, Lagerkrantz S, Lagerkrantz J, Fried G, et al. Human estrogen receptor beta gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-4265.
  9. Huang J, Li X, Yi P, Hilf R, Bambara RA. Muyan M. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol Cell Endocrinol 2004; 218: 65-78.
  10. McKenna NJ, Nawaz Z, Tsai SY, Tsai H-J, O'Malley BW. Distinct steady state nuclear receptor co-regulator complexes exist in vivo. Proc Natl Acad Sci USA 1998; 95: 11697-11702.
  11. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen receptor corepressors: a role in human breast cancer? Endocr Rel Cancer 2003; 10: 517-536.
  12. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001; 61: 903-907.
  13. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995; 9: 443-456.
  14. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen receptor pathways to AP-1. Steroid Biochem Mol Biol 2000; 74: 311-317.
  15. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, et al. Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000; 275: 5379-5387.
  16. Safe S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001; 62: 231-252.
  17. Kuiper GGJM, Carlsson B, Grandieu K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997; 138: 863-870.
  18. Jones PS, Parrott E, White IN. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. J Biol Chem 1999; 274: 32008-320014.
  19. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277: 1508-1510.
  20. Sanchez R, Nguyen D, Rocha W, White JH, Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 2002; 24: 244-254.
  21. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor and insulin-like growth factor signalling in breast cancer. Clin Cancer Res 2001; 7: 4429s-4435s.
  22. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994; 269: 4458-4466.
  23. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 2002; 20: 5041-5047.
  24. Schiff R, Osborne CK. New insights into estrogen receptor-α function and its implications for endocrine therapy resistance in breast cancer. Breast Cancer Res 2005; 7: 205-211.
  25. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977; 265: 69-72.
  26. Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 2003; 88: 438-455.
  27. Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol Endocrinol 2002; 16: 116-127.
  28. Levin ER. Cell localization, physiology and non-genomic actions of estrogen receptors. J Applied Physiol 2001; 91: 1860-1867.
  29. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003; 23: 1633-1646.
  30. Watters JJ, Chun TY, Kim YN, Bertics PJ, Gorski J. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol 2000; 14: 1872-1881.
  31. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors α and β. J Biol Chem 2005; 280: 19704-19710.
  32. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-632.
  33. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, Delellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumour progression. Clin Cancer Res 2006; 12: 6359-6366.
  34. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006; 20: 1996-2009.
  35. Speirs V, Adams IP, Walton DS, Atkin SL. Identification of wild-type and exon 5 deletion variants of estrogen receptor β in normal human mammary gland. J Clin Endocrinol Metab 2000; 85: 1601-1605.
  36. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 2002; 55: 371-374.
  37. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 2002; 198: 450-457.
  38. Walker RA, Cowl J, Dhadly PP, Jones JL. Oestrogen receptor, epidermal growth factor receptor and oncoprotein expression in non-involved tissue of cancerous breasts. Breast 1992; 2: 87-91.
  39. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999; 188: 237-244.
  40. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991; 48: 206-210.
  41. Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 1992; 65: 601-607.
  42. Boyd MT, Hildebrandt RH, Bartow SA. Expression of the estrogen receptor gene in developing and adult human breast. Breast Cancer Res Treat 1996; 37: 243-251.
  43. Cheng G, Li Y, Omoto Y, et al. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 2005; 90: 435-444.
  44. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-4991.
  45. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 2005; 277: 443-456.
  46. Jensen EV, Cheng G, Palmieri C, Sajv S, Makela S, van Noorden S, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001; 98: 15197-15202.
  47. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999; 155: 1811-1815.
  48. Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopoulos D. Low oestrogen receptor α expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet 1999; 354: 1787-1788.
  49. Millis RR, Bobrow LG, Barnes DM. Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: correlation with morphological features and recently proposed schemes for histological classification. Breast 1996; 5: 113-122.
  50. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor-negative human breast cancer. Breast Cancer Res 2004; 6: 240-245.
  51. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004; 15: 193-197.
  52. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537-2541.
  53. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaille R, Molleri C, Warner M, et al. Estrogen receptor beta (ERβ) level but not its ERβ cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10: 5769-5776.
  54. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213-220.
  55. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, et al. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003; 27: 1502-1512.
  56. Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS. Prognostic significance of estrogen receptor β in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 2005; 29: 1593-1599.
  57. Zhao C, Lam EW, Sunters A, Enmark E, DeBella MT, Coombes RC, et al. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003; 22: 7600-7606.
  58. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, et al. Methylation of estrogen receptor beta promoter correlates with loss of ERβ expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 2005; 12: 903-916.
  59. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998; 247: 75-78.
  60. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, et al. The complete primary structure of human estrogen receptor beta (hERβ) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998; 243: 122-126.
  61. Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, et al. Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 2002; 62: 4849-4853.
  62. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin Cancer Res 2005; 11: 3170-3174.
  63. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res 1999; 59: 1175-1179.
  64. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S. Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 2000; 88: 733-736.
  65. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, et al. Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002; 38: 380-386.
  66. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 1998; 26: 3505-3512.
  67. Krege JH, Hodgkin JB, Couse JF, Enmark E, Warner M, Mahler JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA 1998; 95: 15677-15682.
  68. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERα) and estrogen receptor-beta (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 1997; 138: 4613-4621.
  69. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 1978; 253: 2223-2238.
  70. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1284-1291.
  71. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-1979.
  72. Kraus WL, Montana MM, Katzenellenbogen BS. Cloning of the rat progesterone receptor gene 5′ region and identification of two functionally distinct promoters. Mol Endocrinol 1993; 7: 1603-1616.
  73. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor A PR-A rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10: 2751-2760.
  74. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331-3338.
  75. Dowsett M, Johnstone S, Martin L-A, Salter J, Hills M, Detre S, et al. Growth factor signalling and response to endocrine therapy: the Royal Marsden experience. Endocr Relat Cancer 2005; 12: S113-S117.
  76. Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984; 44: 836-840.
  77. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, et al. Non-endocrine pathways and endocrine resistance: observations into anti-oestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10: 346S-354S.
  78. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al. Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142: 2776-2788.
  79. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
  80. Gee JM, Robertson JF, Gutteridge E, Pinder SE, Rubini M, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12: S99-S111.
  81. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
  82. Lannigan D. Estrogen receptor phosphorylation. Steroids 2003; 68: 1-9.
  83. Murphy LC, Niu Y, Snell L, Watson P. Phospho-serine-118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 2004; 10: 5902-5906.
  84. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, et al. Phosphorylation of ER(alpha) at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER(alpha) phosphorylation in breast cancer progression. Endocr Relat Cancer 2006; 13: 851-861.
  85. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, et al. Co-expression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 1999; 59: 525-528.
  86. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999; 59: 5421-5424.
  87. Chen B, Gajdos C, Dardes R, Kidwai N, Johnstone SR, Dowsett M, et al. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERβ complex. Int J Oncol 2005; 27: 327-335.
  88. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, et al. Inducible up-regulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34: 553-666.
  89. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, et al. Estrogen receptor β expression in invasive breast cancer. Hum Pathol 2001; 32: 113-118.
  90. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490-7499.
  91. Cappelletti V, Celio L, Bajetta E, Allevi A, Longarini R, Miodini P, et al. Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer 2004; 11: 761-770.
  92. Palmieri C, Lam EW, Mansi J, Cheng G, Sunters A, O'Hare MJ, et al. The expression of ER βcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004; 10: 2421-2428.
  93. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, Western blotting and flow cytometry in human breast tissue. J Pathol 2002; 197: 155-162.
  94. Carder PJ, Murphy CE, Dervan P, Kennedy M, McCann A, Saunders PTK, et al. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERβ in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat 2005; 92: 287-293.
  95. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, et al. Assessment of multiple different estrogen receptor-β antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 2006; 100: 23-31.
  96. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, et al. Estrogen receptor (ER)β reduces ERα-regulated gene transcription, supporting a ‘ying yang’ relationship between ERα and ERβ in mice. Mol Endocrinol 2003; 17: 203-208.
Article Info
Journal
The Journal of pathology
Abbr.
J Pathol
ISSN
0022-3417
DOI
10.1002/path.2130
Published
2007-04-00
Pages
499-506
Language
English
Region
England
NLM ID
0204634
Subset
IM
External Links
PubMed source DOI: 10.1002/path.2130 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2